Our main findings can be summarized as follows: (a) the systemic delivery of Bry‐1 ameliorated experimental colitis by attenuating intestinal barrier injury and the abnormal intestinal mucosal immune response in Il‐10−/− mice; and (b) the effects of Bry‐1 on spontaneous chronic colitis may be partly mediated through activating Nrf2 signalling and downregulating STAT3/4 signalling. The gene discussed is IL10; the disease is Chronic colitis.